Dr. Chris Mason
Chris Mason, MBBS, Ph.D., FRCS is an
international expert on the translational and commercial aspects of
regenerative medicine, tissue engineering, and stem cell technologies.
He is based at the
Stem Cell + Regenerative Medicine Bioprocessing Unit,
Advanced Centre for Biochemical Engineering,
University College London.
Chris is at the forefront of the emerging field of stem cell and
regenerative medicine bioprocessing plus is involved in a number of
committees, networks, scientific advisory boards, editorial boards,
working groups, and initiatives related to the academic, clinical, and
commercial advancement of stem cells and tissue
engineering.
Originally graduating from Imperial College with a degree in molecular
biology and the St. Thomas Hospital Medical School with a medical
degree,
Chris then specialized in surgery. He is a Fellow of the Royal
College of Surgeons of England, Fellow of the Royal College of Surgeons
in Ireland and a Fellow of the Royal Society of Medicine. In addition,
he earned a PhD in Biochemical Engineering under the supervision of
Professor
Peter Dunnill (UCL). He coordinates the Stem Cell + Regenerative
Medicine
(“RegenMed”) Bioprocess Group at UCL (a team of 20 researchers) and has
broad range of expertise in commercial consultancy. Furthermore, he
has over 10 years of experience at the boardroom level of running
technology
companies.
Chris is also cofounder and co-organizer (with our
Stephen Minger) of
the
London Regenerative
Medicine Network (LRMN), on the Editorial Boards of the journals
Regenerative Medicine,
Nanomedicine,
Medical Device Technology, and
Tissue Engineering, Mission
Leader of the
DTI funded Global Watch Mission “Advanced Cell & Tissue Therapies” which
visited to the West Coast of North America in September 2006, and a
member of the Steering Committee for the UK National Stem Cell Network
(UKNSCN).
He authored
Regenerative Medicine — The Industry Comes of Age,
Regenerative Medicine 2.0, and
A Blueprint for the Future,
and
coauthored
A brief definition of regenerative medicine,
Lessons for the nascent regenerative medicine industry from
the biotech sector,
Good for UK health and wealth,
International community consensus standard for reporting derivation
of
human embryonic stem cell lines,
Mapping the human embryome: 1 to 10e13 and all the cells in
between,
Translational Regenerative Medicine Research: Essential to Discovery
and Outcome, and
Proposal for a universal minimum information convention for the
reporting on the derivation of human embryonic stem cell lines.
Read
Stem cells made to mimic disease.
